Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PLUR with free AI briefings, catalyst countdowns, and dilution alerts.

PLUR · Pluri Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8.7M Cash on Hand
5.8mo Cash Runway
Follow PLUR by email Get an email when PLUR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PLUR, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

PLUR holds $8.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.5M/quarter from operations, an estimated runway of 5.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PLUR files for a raise →

👥 Who Owns PLUR

Insiders 21.3% Other 5%+ holders 49.1% Institutions (20 holders) 20.7% Public and other holders 8.9%
HolderTypeShares% of sharesAs of
Alexandre Weinstein 5%+ holder (13D) 4,561,616 31.73% 2026-10-23
Chutzpah Holdings LP 5%+ holder (13D) 2,500,000 17.39% 2026-04-21
Alexandre Weinstein Manieu
Director, 10% owner · +3.27M options
Insider 2,090,900 14.54% 2026-08-25
Armistice Capital, LLC Institution (13G, 5%+) 1,266,508 8.81% 2026-09-30
Yaky Yanay
Chief Executive Officer, Director · +39,050 options
Insider 498,594 3.47% 2025-12-04
Zami Aberman
Director
Insider 155,684 1.08% 2025-12-04
Liat Zalts
Chief Financial Officer
Insider 92,767 0.65% 2025-12-04
Chen Franco-Yehuda
Chief Financial Officer
Insider 67,503 0.47% 2024-09-18
Doron Shorrer
Director
Insider 45,197 0.31% 2026-08-20
Lorne Kenneth Abony
Director
Insider 36,750 0.26% 2024-01-23
Pinhas Doron Birger
Director
Insider 19,178 0.13% 2025-02-25
Maital Shemesh-Rasmussen
Director
Insider 19,144 0.13% 2025-12-04

Share count 14,375,922 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PLUR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PLUR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.